This is a mechanism module, not a specific disease, and conformance is node-level consistency rather than inheritance. The operational splice-branch boundary below is a curation guardrail, not a formal schema or Grouping criterion. Use "antisense_oligonucleotide_therapy#Pathogenic Pre-mRNA Missplicing" only for an evidence-backed disease-, variant-, or subgroup-specific abnormal splice event, and use "antisense_oligonucleotide_therapy#Exon-Skipping-Addressable Reading-Frame Lesion" for a genomic reading-frame lesion whose pre-mRNA is a substrate for therapeutic exon skipping without claiming abnormal basal splicing. In either branch, the disorder entry must duplicate the conserved vulnerability-to-ASO-effector-to-productive-output chain with disease-specific nodes and causal edges; the treatment must also target the exact RNA vulnerability through an evidence-bearing target_mechanisms link. Every vulnerability-to-effector edge is conditional on administration of the sequence-matched ASO and must say so explicitly. Prefer direct evidence that the ASO redirects the named splice event toward a productive transcript. When the cached evidence establishes only molecular eligibility and downstream protein production, mark the exact RNA-target link PARTIAL and state that limitation. If evidence establishes restored productive RNA and cellular function but does not measure protein expression, retain the disease-specific consequence without conforming it to the module protein-expression outcome and do not add an unsupported translation modifier merely to complete the chain. A modality tag, a downstream protein deficit, or clinical benefit alone is not sufficient. In scope here are exon-skipping-amenable DMD transcripts, whose genomic reading-frame lesion creates a targetable pre-mRNA processing vulnerability without implying globally abnormal basal splicing, and the patient-specific MFSD8 cryptic splice-acceptor event targeted by milasen. Exclude siRNA/RNAi, splice-modifying small molecules, and ASOs whose operative mechanism is lncRNA unsilencing, upstream-open-reading-frame blockade, or epigenetic de-repression. The RNase H and viral-translation branches are retained as descriptive module content, but new conformers to those branches are deferred until their trigger semantics and drug-specific evidence are separately reconciled; in particular, do not map fomivirsen while its RNase H versus steric-blockade classification remains contradictory in the cached evidence. Spinal muscular atrophy and nusinersen are also deliberately deferred: their compensatory SMN2 exon-inclusion vulnerability requires a separately curated anchor and must not be presumed to conform to the disease-causal missplicing anchor used here.
Pathogenic mRNA Accumulation
trigger
In dominant gain-of-function or toxic protein overexpression diseases, the causal mRNA is transcribed and translated at a level that produces harmful amounts of the encoded protein. The transcript itself is structurally normal but its abundance or the toxicity of its protein product is the pathogenic driver — making mRNA level reduction, rather than protein inhibition, the upstream therapeutic target. Examples include SOD1 mRNA in SOD1-ALS, TTR mRNA in hereditary transthyretin amyloidosis, APOB mRNA in homozygous familial hypercholesterolemia, APOC3 mRNA in familial chylomicronemia syndrome, KLKB1 (prekallikrein) mRNA in hereditary angioedema, and FUS mRNA in FUS-ALS. RNase H-dependent ASOs bind the target mRNA and recruit endogenous RNase H1 to cleave the heteroduplex, degrading the message and reducing the pathogenic protein.
Downstream
-
RNase H-Mediated Transcript Degradation
The ASO base-pairs with the target mRNA, forming a DNA:RNA heteroduplex that recruits endogenous RNase H1 to cleave the RNA strand.
Reduction of Pathogenic Protein
consequence
RNase H-mediated mRNA cleavage reduces ribosomal substrate availability, producing a sustained, dose-dependent reduction in the pathogenic protein. The magnitude of protein reduction is the primary pharmacodynamic readout: tofersen reduces CSF SOD1; inotersen and eplontersen reduce serum TTR; mipomersen reduces LDL-C via APOB reduction; volanesorsen and olezarsen reduce APOC3 and serum triglycerides; donidalorsen reduces prekallikrein. Protein reduction translates to disease modification when the targeted protein is the proximate pathogenic driver.
Pathogenic Pre-mRNA Missplicing
therapeutic vulnerability
A disease-, variant-, or subgroup-specific pre-mRNA is processed through an abnormal splice event, such as activation of a cryptic splice acceptor or pathogenic exclusion of an exon. The missplicing is part of the untreated disease mechanism and creates a sequence-specific therapeutic vulnerability when a steric ASO can occlude the responsible regulatory element. This anchor is not for genomic reading-frame lesions whose basal splice-site use is normal.
Downstream
-
ASO-Directed Splice Redirection
When a sequence-matched splice-switching ASO is administered, occupancy of the pathogenic splice element redirects exon choice toward a productive transcript. This is an intervention-conditioned edge, not an untreated consequence of the missplicing defect.
Exon-Skipping-Addressable Reading-Frame Lesion
therapeutic vulnerability
A genomic exon deletion or related lesion shifts the coding frame, yielding an out-of-frame mature transcript and prematurely truncated dysfunctional protein. Basal splice-site use need not be abnormal. The therapeutic vulnerability is the pre-mRNA state in which controlled skipping of one additional, genotype-specific exon can restore an in-frame transcript. This anchor applies only to molecularly amenable genotypes, not to the disorder generally.
Downstream
-
ASO-Directed Splice Redirection
When a matching exon-skipping ASO is administered to an amenable genotype, steric occlusion of the selected exon redirects pre-mRNA processing toward an in-frame transcript. This is an intervention-conditioned edge, not a consequence of the untreated genomic lesion alone.
ASO-Directed Splice Redirection
effector
After administration to a patient with the matching RNA vulnerability, a steric-blocking ASO (uniformly modified; no RNase H recruitment) binds a splice regulatory element on the pre-mRNA — a splice acceptor, splice donor, exonic splicing silencer, or intronic silencing sequence — and physically prevents spliceosome recognition. The spliceosome bypasses the blocked element, either skipping a mutation-bearing exon (exon-skipping paradigm) or including a normally silenced exon (exon-inclusion paradigm). Phosphorodiamidate morpholino oligomer (PMO) chemistry, used in the DMD exon-skipping ASOs, is uncharged and cell-penetrant without lipid formulation, while 2'-MOE chemistry (used in nusinersen) supports intrathecal delivery to motor neurons.
Downstream
-
Restored Productive Transcript and Protein Expression
Treatment-induced splice redirection yields an in-frame mRNA that can be translated into a truncated but partially functional protein, or restores full-length protein when an inclusion event is achieved.
Restored Productive Transcript and Protein Expression
consequence
Under treatment with the matching splice-switching ASO, redirection increases a productive transcript and functional output from its encoded protein. In DMD exon skipping, the resulting dystrophin is shorter than wild type but in frame and partially functional. Correction of a cryptic splice acceptor, as in the single milasen-treated NCL7 patient, instead restores the normal exon junction, avoids premature translational termination, and can rescue cellular function even when protein abundance is not directly quantified. Exon-inclusion strategies can restore a full-length protein. This node describes the shared productive-transcript outcome without claiming that every strategy restores a literal genomic reading frame or a full-length protein.
Used by disorders
Werner Syndrome
as Restored Partial WRN Expression and Nuclear Localization
Pathogenic Viral mRNA Translation
trigger
In viral infections where the pathogenic protein is virus-encoded rather than host-encoded, an ASO can sterically block translation of the viral mRNA without recruiting RNase H. This generic paradigm differs from host-gene RNase H knockdown because the target is an exogenous transcript and the therapeutic window relies on viral-sequence specificity. Fomivirsen is not treated as an example or conformer here: the review cited below discusses steric blockade as a general ASO mechanism but classifies fomivirsen itself as RNase H dependent, so its drug-specific placement must be resolved with direct evidence before curation.
Downstream
-
Steric Viral mRNA Translation Blockade
The ASO base-pairs with the viral mRNA target site, physically impeding ribosome scanning or 48S complex assembly without cleaving the transcript.
Steric Viral mRNA Translation Blockade
effector
The ASO:viral mRNA duplex physically impedes ribosomal access to the translation initiation region or coding sequence without recruiting RNase H. Because the RNA strand is not cleaved, this mechanism requires sustained ASO occupancy at the target site. The steric blockade reduces viral immediate-early gene product levels, disrupting the transcriptional amplification cascade essential for productive viral replication. This paradigm is now largely superseded by RNase H knockdown and small-molecule antivirals for most viral targets, but established the proof of concept for ASO therapeutics.